Breaking Down SG&A Expenses: Pfizer Inc. vs Exelixis, Inc.

A Tale of Two Giants: SG&A Expenses in the Pharmaceutical Industry

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. Pfizer Inc., a titan in the sector, consistently allocates a significant portion of its revenue to Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A expenses have shown a steady trend, peaking at approximately $14.8 billion in 2016 and 2023. This reflects a strategic focus on maintaining its market dominance through robust administrative and sales efforts.

In contrast, Exelixis, Inc., a smaller yet dynamic player, has seen its SG&A expenses grow by over 900% during the same period, from $50 million in 2014 to $542 million in 2023. This surge underscores Exelixis's aggressive expansion strategy and its commitment to scaling operations. The juxtaposition of these two companies offers a fascinating glimpse into the diverse strategies employed within the pharmaceutical industry.